Identification of unique expression signatures and therapeutic targets in esophageal squamous cell carcinoma

BackgroundEsophageal squamous cell carcinoma (ESCC), the predominant histological subtype of esophageal cancer, is characterized by high mortality. Previous work identified important mRNA expression differences between normal and tumor cells; however, to date there are limited ex vivo studies examining expression changes occurring during normal esophageal squamous cell differentiation versus those associated with tumorigenesis. In this study, we used a unique tissue microdissection strategy and microarrays to measure gene expression profiles associated with cell differentiation versus tumorigenesis in twelve cases of patient-matched normal basal squamous epithelial cells (NB), normal differentiated squamous epithelium (ND), and squamous cell cancer. Class comparison and pathway analysis were used to compare NB versus tumor in a search for unique therapeutic targets.ResultsAs a first step towards this goal, gene expression profiles and pathways were evaluated. Overall, ND expression patterns were markedly different from NB and tumor; whereas, tumor and NB were more closely related. Tumor showed a general decrease in differentially expressed genes relative to NB as opposed to ND that exhibited the opposite trend. FSH and IgG networks were most highly dysregulated in normal differentiation and tumorigenesis, respectively. DNA repair pathways were generally elevated in NB and tumor relative to ND indicating involvement in both normal and pathological growth. PDGF signaling pathway and 12 individual genes unique to the tumor/NB comparison were identified as therapeutic targets, and 10 associated ESCC gene-drug pairs were identified. We further examined the protein expression level and the distribution patterns of four genes: ODC1, POSTN, ASPA and IGF2BP3. Ultimately, three genes (ODC1, POSTN, ASPA) were verified to be dysregulated in the same pattern at both the mRNA and protein levels.ConclusionsThese data reveal insight into genes and molecular pathways mediating ESCC development and provide information potentially useful in designing novel therapeutic interventions for this tumor type.

[1]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[2]  K. Mafune,et al.  Structures of the normal esophagus and Barrett’s esophagus , 2003, Esophagus.

[3]  Guidel Ines,et al.  Expression profiling — best practices for data generation and interpretation in clinical trials , 2004, Nature Reviews Genetics.

[4]  B. Scheithauer,et al.  Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues , 2010, Endocrine pathology.

[5]  G. Stark,et al.  Analyzing the G2/M checkpoint. , 2004, Methods in molecular biology.

[6]  Isaac S. Kohane,et al.  Comprehensive Dissection of PDGF-PDGFR Signaling Pathways in PDGFR Genetically Defined Cells , 2008, PloS one.

[7]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[8]  The eMERGE Clinical Annotation Working Group,et al.  Expression profiling — best practices for data generation and interpretation in clinical trials , 2004 .

[9]  I. Ellis,et al.  Immunohistochemical analysis reveals a tumour suppressor‐like role for the transcription factor AP‐2 in invasive breast cancer , 1999, The Journal of pathology.

[10]  J. Gillespie,et al.  Identification of a unique epigenetic sub‐microenvironment in prostate cancer , 2007, The Journal of pathology.

[11]  M. Emmert-Buck,et al.  Immunoguided microdissection techniques. , 2011, Methods in molecular biology.

[12]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[13]  Tobias Sjöblom,et al.  PDGF receptors as cancer drug targets. , 2003, Cancer cell.

[14]  T. Hupp,et al.  Adaptive Evolution of a Stress Response Protein , 2007, PloS one.

[15]  M. Emmert-Buck,et al.  Identification of EpCAM as a molecular target of prostate cancer stroma. , 2009, The American journal of pathology.

[16]  J. Gillespie,et al.  Assessment of normalization strategies for quantitative RT-PCR using microdissected tissue samples , 2007, Laboratory Investigation.

[17]  Lynda F. Bonewald,et al.  Identification and Characterization of a Novel Protein, Periostin, with Restricted Expression to Periosteum and Periodontal Ligament and Increased Expression by Transforming Growth Factor β , 1999 .

[18]  H. Tabuchi,et al.  5-Fluorouracil up-regulates interferon pathway gene expression in esophageal cancer cells. , 2005, Anticancer research.

[19]  Stanley R. Hamilton,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[20]  H. Nakshatri,et al.  Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. , 1999, Biochemical and biophysical research communications.

[21]  Tatjana Crnogorac-Jurcevic,et al.  Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer , 2003, Oncogene.

[22]  N. Hu,et al.  High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China. , 2000, Carcinogenesis.

[23]  Li Mao,et al.  Transcriptomic dissection of tongue squamous cell carcinoma , 2008, BMC Genomics.

[24]  M. Sheikh,et al.  Death Receptor Activation Complexes: It Takes Two to Activate TNF Receptor 1 , 2003, Cell cycle.

[25]  D. Matei,et al.  Imatinib Mesylate (Gleevec) Inhibits Ovarian Cancer Cell Growth through a Mechanism Dependent on Platelet-Derived Growth Factor Receptor α and Akt Inactivation , 2004, Clinical Cancer Research.

[26]  Young-Joon Kim,et al.  Expression patterns of aurora kinase B, heat shock protein 47, and periostin in esophageal squamous cell carcinoma. , 2009, Oncology Research.

[27]  R. Agarwal,et al.  Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  P. Glazer,et al.  Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. , 1998, Cancer research.

[29]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[30]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[31]  W. Travis.  Pathology of lung cancer. , 2002, Clinics in chest medicine.

[32]  P R Taylor,et al.  Cytologic detection of esophageal squamous cell carcinoma and precursor lesions using balloon and sponge samplers in asymptomatic adults in Linxian, China , 1997, Cancer.

[33]  L. Aaltonen,et al.  Pathology and genetics of tumours of the digestive system , 2000 .

[34]  Terri Goss Kinzy,et al.  Characterization of genetic alteration patterns in human esophageal squamous cell carcinoma using selected microsatellite markers spanning multiple loci. , 2007, International journal of oncology.

[35]  Lawrence C. Brody,et al.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage , 2002, Nature Genetics.

[36]  R. Simon,et al.  An investigation of two multivariate permutation methods for controlling the false discovery proportion , 2007, Statistics in medicine.

[37]  A. Tomida,et al.  Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia , 2001, Oncogene.

[38]  M. Emmert-Buck,et al.  Effect of Immunohistochemistry on Molecular Analysis of Tissue Samples , 2011, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[39]  B. Friedenson,et al.  The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers , 2007, BMC Cancer.

[40]  Paola Pisani,et al.  Estimates of the world‐wide prevalence of cancer for 25 sites in the adult population , 2002, International journal of cancer.

[41]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Jaime Rodriguez-Canales,et al.  Quantitative RT-PCR gene expression analysis of laser microdissected tissue samples , 2009, Nature Protocols.

[43]  Jaime Rodriguez-Canales,et al.  Global Expression Analysis of Prostate Cancer-associated Stroma and Epithelia , 2007, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[44]  Ying Liang,et al.  Enhanced Interferon Signaling Pathway in Oral Cancer Revealed by Quantitative Proteome Analysis of Microdissected Specimens Using 16O/18O Labeling and Integrated Two-dimensional LC-ESI-MALDI Tandem MS* , 2009, Molecular & Cellular Proteomics.

[45]  K. Ogawa,et al.  Molecular profiles of the mouse postnatal development of the esophageal epithelium showing delayed growth start. , 2006, International journal of molecular medicine.

[46]  R. Riddell,et al.  The normal esophagus. , 1991, The American journal of surgical pathology.

[47]  M. Wang,et al.  Novel human esophagus-specific gene c1orf10: cDNA cloning, gene structure, and frequent loss of expression in esophageal cancer. , 2000, Genomics.

[48]  Richard Simon,et al.  Gene expression-based prognostic signatures in lung cancer: ready for clinical use? , 2010, Journal of the National Cancer Institute.

[49]  P. Hainaut,et al.  Squamous cell carcinoma of the oesophagus , 2006 .

[50]  M. Caruso,et al.  Methylation of TIMP3 in esophageal squamous cell carcinoma. , 2008, World journal of gastroenterology.

[51]  T. Hastie,et al.  Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis , 2002, BMC Genomics.

[52]  K. Buetow,et al.  Genome-wide loss of heterozygosity and copy number alteration in esophageal squamous cell carcinoma using the Affymetrix GeneChip Mapping 10 K array , 2006, BMC Genomics.

[53]  David B. Krizman,et al.  The genetics of cancer—a 3D model , 1999, Nature Genetics.

[54]  A. Nakao,et al.  Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma. , 2006, Anticancer research.

[55]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[56]  R. Grafström,et al.  Multiple genotypic aberrances associate to terminal differentiation-deficiency of an oral squamous cell carcinoma in serum-free culture. , 2008, Differentiation; research in biological diversity.

[57]  P. Russell,et al.  Diagnosis of second head and neck tumors in primary laryngeal SCC is an indicator of overall survival and not associated with poorer overall survival: A single centre study in 987 patients , 2010, Journal of surgical oncology.

[58]  Yu Liu,et al.  Enhanced proliferation, invasion, and epithelial-mesenchymal transition of nicotine-promoted gastric cancer by periostin. , 2011, World journal of gastroenterology.

[59]  Nan Hu,et al.  Genomic characterization of esophageal squamous cell carcinoma from a high-risk population in China. , 2009, Cancer research.

[60]  D. Huntsman,et al.  IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype , 2009, Modern Pathology.

[61]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[62]  K. Horiuchi,et al.  Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  Edward S. Kim,et al.  Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial , 2008, Cancer Prevention Research.